Syndax switches first-line plans
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Baili moves its CD33 conjugate into advanced trials
The company is set to start a phase 2/3 trial this month.
ASH 2025 – Kura seeks further safety edge
The company will try to get the Komzifti QTc prolongation warning removed.
ASH 2025 preview – a new menin battleground
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
Kura joins the pivotal menin push
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
